Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-24T05:19:59.359Z Has data issue: false hasContentIssue false

TEGRETOL

Published online by Cambridge University Press:  18 September 2015

Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Other
Copyright
Copyright © Canadian Neurological Sciences Federation 1997

References

1.Ignatowicz, L, Ignatowicz, R, Jozwiak, Ret al. Psychiatric aspects of epilepsy in childhood treated with Tegretol CR (Ciba-Geigy) (Abstr. of paper). Epilepsia (USA) 1995;36(3):S128–S129.Google Scholar
2.De deyn Peter, Mol L, et al. An open multicenter prospective study of the effects of monotherapy with controlled-release carbamazepine on newly diagnosed generalized tonic&-clonic seizures. Seizure 1994;3:235238.Google Scholar
3.Eeg-Olofsson, O, Nilsson, H, Tonnby, B, et al. Diurnal variation of carbamazepine and carbamazepine-10,11- epoxide in plasma and saliva in children with epilepsy: A comparison between conventional and slow-release formulations. Jrnl Child Neurol (USA) 1990;5(2):159165.CrossRefGoogle ScholarPubMed
4.Tegretol® Product Monograph, November 1995.Google Scholar
5.Aldenkamp, et al. Controlled release carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia 1987;28(3):507514.Google Scholar
6.Dhalla, Z, Bruni, J, Sutton, J. A comparison of the efficacy and tolerability of controlled-release carbamazepine. Cdn Jrnl Neurl Sciences 1991;18:6668.Google Scholar
7.Canger, R, Altamura, AC, Belvedere, O, Monaco, F, Monza, GCet al. Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study. Acta Neurol Scand 1990;82:913.Google Scholar